Twice weekly carfilzomib is an accepted treatment by patients with Multiple Myeloma who have received at least one prior therapy: Interim results if the CARO study. 29. Juli 2019 W. Knauf; A. Ammon; J. Uhlig; M. Merling; H.-J. Hurtz; T. Riedt; H. Schulz; C. Vannier; N. Marschner; K. Potthoff; 2019. HemaSphere. 3():646–647, JUN 2019 DOI: 10.1097/01.HS9.0000563904.96659.51 Issn Print: 2572-9241 Abstract Download Lenalidomide in combination with dexamethasone as first-line therapy in transplant-ineligible patients with Multiple Myeloma: Interim Results of the observational study FIRST-NIS. H. Nückel; H.-J. Hurtz; H. Schulz; M. Schulze; M. Koenigsmann; T. Dechow; M. Merling; L. Houet; C. Vannier; K. Potthoff; 2019. HemaSphere. 3():263–264, JUN… Weiterlesen A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results. C C Schimanski, S Kasper, S Hegewisch-Becker, J Schroeder, F Overkamp, F Kullmann, W O Bechstein, M Vöhringer, R Oellinger, F Lordick, V Heinemann, M… Weiterlesen